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The recognition, evaluation, and early treatment of nephrotic syndrome in infants and 
children originate from physicians dating back to Hippocrates. It took nearly another 
1000 years before the condition was described for its massive edema requiring treat-
ment with herbs and other remedies. A rich history of observations and interpretations 
followed over the course of centuries until the recognition of the combination of clinical 
findings of foamy urine and swelling of the body, and measurements of urinary protein 
and blood analyses showed the phenotypic characteristics of the syndrome that were 
eventually linked to the early anatomic descriptions from first kidney autopsies and 
then renal biopsy analyses. Coincident with these findings were a series of treatment 
modalities involving the use of natural compounds to a host of immunosuppressive 
agents that are applied today. With the advent of molecular and precision medicine, the 
field is poised to make major advances in our understanding and effective treatment of 
nephrotic syndrome and prevent its long-term sequelae.
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HiSTORY OF NePHROTiC SYNDROMe
Nephrotic syndrome, as we know it today, is a combination of proteinuria, hypoalbuminemia, hyper-
lipidemia, and edema, a concept that took some time to be developed. Interestingly, the effective 
treatments became available only recently in the mid 1900s, with the advent of steroids, antibiotics, 
diuretics, and other immunomodulators. Even today, there is a gap in our understanding of the 
etiology(s) of nephrotic syndrome of childhood, and better treatments are still required in the more 
resistant forms. Nephrotic syndrome as such is a combination of clinical and laboratories findings 
that is seen with a variety of pathologic lesions affecting the glomerulus.
Generalized edema, referred to as dropsy in the earlier literature, has been documented from the 
times of Hippocrates (1, 2), although the differentiation between various causes (heart vs. liver vs. 
nutritional disturbances vs. renal abnormalities) was not made. One observation by Hippocrates 
was: “when bubbles settle on the surface of the urine, it indicates a disease of the kidney and that the 
disease will be protracted” (1). Cornelus Roelans of Belgium described in 1484 a child with nephrotic 
syndrome and “whole body swelling.” He went on to recommend the treatment as follows: “take the 
tops of elder plant and daneswort, cook in white wine and wrap the child in hot clothes by applying 
the poultice in whole or in part, and so cure him” (3).
During the sixteenth to eighteenth centuries, dropsy was considered a disease per se, the patient 
had dropsy, without differentiating between the causes (4). One of the first accurate descriptions 
of nephrotic syndrome in children was made by Theodore Zwinger of Basel in 1722 (5). He also 
noted decreased urine output and attributed this to “obstruction and compression of the tubules of 
the kidney,” thus placing the seat of the disease in the kidney, since at that time, it was recognized 
that in pediatric practice heart and liver disease rarely manifest. His important observation had 
little influence on the scientific community, and his findings were not quoted by any author in 
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the following 200 years. Of note, these observations were made 
even before Morgagni was able to establish the idea that disease 
might arise from specific organs (6). Morgagni’s disciple William 
Heberden went on to say: “Dropsy is very rarely an original 
distemper but generally a symptom of some other which is too 
often incurable” (7).
Later in the eighteenth century, dropsy was divided into those 
dependent on morbid viscera (liver and heart) and a general 
form, supposedly inflammatory. With humoralism, a prevalent 
concept in Europe at that time, bloodletting was a common 
practice for these so called “inflammatory diseases” and was a 
commonly prescribed. Around the same time, several observers 
[namely, Cotugno (8), Cruikshank (9), Wells (10), and Brande 
(9)] noted coagulability of urine in the patients. It was finally in 
1827 that Richard Bright (1789–1858) was able to put together 
the triad of generalized edema, proteinuria, and kidney disease, 
as presenting features of this disease (11). John Bostock, a col-
league of Bright, also noted that when protein in the urine was 
highest, it was lowest in the serum (11). Christison confirmed 
these findings in 1829 (12). Hence by 1830, nephrotic syndrome 
of profound albuminuria, hypoalbuminemia, and edema, result-
ing from diseased kidneys was established. Subsequently, on the 
postmortem analysis, these kidneys revealed a diseased state. 
Bright described three varieties of postmortem appearance of 
the kidneys, Chritison seven, Pierre Rayer six in 1840, and Carl 
Rokitansky no less than eight in 1846, including the “specknierre” 
or bacon kidney, recognized later as amyloidosis (9).
Over the next few years, the various lipid abnormalities 
in nephrotic syndrome became the forefront of discussion. 
Latescent or milky appearance of the serum was known to be 
present in nephrotic syndrome (noted with bloodletting ses-
sions). Christison showed this to be from ether soluble fat (13). In 
1846, Johnson not only described the fatty nature of the kidneys 
on gross appearance in many such patients but also fat globules 
and fat casts in the tubules (14). More attention was given to the 
cellular and tubular components of the kidneys as they were more 
obvious by the histological techniques available at that time.
Virchow introduced the term “parenchymatous nephritis” for 
a pathological picture with primary tubular involvement (15). 
With advances in microscopy, glomerular involvement became 
clearer along with that of the parenchyma. In acute nephritis, the 
presence of pale exsanguinated glomeruli was long known. In 
1872, Klebs coined the term “glomerulonephritis” to describe the 
exudative glomerular changes seen under the microscope (16). 
In 1905, the term “nephrosis” was coined by Müller to describe 
all “non-inflammatory” diseases of the kidney as a substitute 
for parenchymatous nephritis, contrasting it with exudative and 
inflammatory disease, which would retain the name nephritis 
(17). This concept of “nephritis in contrast to nephrosis” was 
further popularized by F. Volhard, T. Fahr, and C. Munk.
TReATMeNTS FOR NePHROTiC 
SYNDROMe
Introduction of the renal biopsy in the mainstream clinical 
practice of nephrology during the 1950s–1960s added a new 
dimension to the understanding of the histological findings in 
nephrotic syndrome. The histological classifications were based 
on the light microscopic appearance and included membranous 
glomerulonephritis, proliferative glomerulonephritis, a mixed 
membranous and proliferative glomerulonephritis, diabetic 
nephropathy with hyaline nodules, and focal segmental glo-
merular sclerosis; these are summarized in a case series from 
1958 (18). The availability of electron microscopy and immuno-
fluorescent localization of proteins was a welcomed coincidence. 
These new techniques transformed the ideas on morphology 
and pathogenesis, and made definite correlations between 
clinical presentation and pathological picture. The 1961, a Ciba 
Foundation symposium on the use of the renal biopsy was a 
landmark in these regards (19).
Antibiotics played an important role in treating the infections 
that arose from nephrotic syndrome, and the mortality rate 
reduced drastically from two-third to 35% (20). It is important to 
point out that prior to availability of steroids multiple desperate 
treatments were tried. A study from Boston noted the various 
treatments that were attempted from 1926 to 1948 for nephrotic 
syndrome. Dietary modification and low salt diet were prob-
ably the most effective treatments at that time. There were some 
weak mercurial diuretics with little if any action. Other drastic 
measures, such as the induction of measles and vaccinia, were 
instituted. Many of the children inoculated had some form of 
post-infection diuresis and decrease in proteinuria (11 out of 
14), only to recur. Other supportive measure included blood 
transfusions, antibiotic therapy, treatment with thyroid extract, 
decapsulation of the kidney, testosterone, multiple vitamins, 
horse antiserum, and parathyroid hormone.
Steroid hormones were first isolated and identified in 1936 
(21, 22). By 1946, cortisone was first prepared by partial synthesis 
from bile acids (23). On the other hand, adrenocorticotropic hor-
mone (ACTH) was extracted from pig and sheep pituitary gland 
by isoelectric precipitation (22, 24) in the 1940s. One prepara-
tion of ACTH was commercially available as sterile powder 
reconstituted with isotonic saline for intramuscular injection. In 
the early 1950s, intramuscular injections of Cortisone (25) and 
ACTH (26) were first being used for treatment for nephrotic 
syndrome in children by Arneil and Wilson from Glasgow. 
These were relatively short courses, 5 days of daily 100–300 mg 
of intramuscular cortisone in the first study and 40–80 mg of an 
ACTH intramuscular injection for 12 days in the second study 
(25, 26). Later on, prednisone was first synthesized by oxidation 
of cortisone (27, 28). ACTH and cortisone were quickly replaced 
by prednisolone and prednisone as they could be administered 
orally without the need for daily injections (29, 30). With the 
advent of steroid therapy, mortality from nephrotic syndrome 
dramatically decreased to 3% (31).
An important series of studies, in the era after renal biopsy 
and steroids, to better understand the management of childhood 
nephrotic syndrome were heralded by the International Study of 
Kidney Disease in Children (ISKDC) established in 1965 with 
participants from North America, Europe, and Asia. A series 
of prospective, multicenter cooperative studies by the ISKDC 
established definitions, clinicopathological correlations, and 
recommendations for therapy that provided a basis for diagnosis 
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and management of pediatric nephrotic syndrome that persists 
today. Between January 1967 and June 1974, children with the 
nephrotic syndrome who were older than 12 weeks and younger 
than 16  years were enrolled into the clinical survey from the 
24 participating clinics (32–34). Of the 521 entered, 76.6% had 
minimal-change nephrotic syndrome, 7.5% had membrano-
proliferative glomerulonephritis, and 6.9% had focal segmental 
glomerulosclerosis (35). All participants had biopsies prior to 
starting steroid therapy with prednisone. Initial treatment was 
60 mg/24 h/m2 (maximum dosage 80 mg/24 h) in divided doses 
for 4 weeks, followed by 40 mg/24 h/m2 in divided doses, three 
consecutive days out of seven for 4 weeks. A seminal observation 
was made that patients with non-minimal lesions had a varied 
and limited response to steroids (36).
Azathioprine, a purine synthesis inhibitor, was also tested by 
this group in a randomized placebo-controlled trial (37). Patients 
that were considered to be early non-responders to steroids (not 
responding to the initial 8-week therapy) or frequently relapsing 
were randomized to receive every other day prednisone with aza-
thioprine (test group) or placebo (control group). No significant 
decrease in proteinuria or number of relapses was noted in the 
test group vs. the control group (37).
The use of an alkylating agent in steroid-resistant nephrotic 
syndrome was first initiated with nitrogen mustard as early as 
1958 (38). This was extended to other alkylating agents, cyclo-
phosphamide and chlorambucil, in the 1960s and prompted the 
ISKDC to conduct a randomized control trial to define the role 
of cyclophosphamide in children with early non-responders and 
frequently relapsing nephrotic syndrome. Cyclophosphamide 
was shown to remit proteinuria in early non-responders and 
decrease the number of relapses of nephrotic syndrome (39). 
Thus, it proved to be an important agent to decrease steroid use 
and prevent steroid toxicity, although it caused gonadal failure in 
post-pubertal males (39). Chorambucil, although noted to be as 
effective as cyclophosphamide (40), had concerning side effects 
of acute leukemia and renal carcinoma (41).
The initial 8-week steroid regimens (4 weeks daily and 4 weeks 
every other day) were then compared with a longer steroid 
treatment duration in the late 1980s (42). Mounting evidence 
 supported a longer duration of steroids, which helped decrease 
the number of future relapses and steroid dependence, and the 
initial 8-week steroid regimen has been recommended to be 
increased to at least 12 weeks (43, 44).
Levamisole, known for its anthelmintic, was first reported to 
be used in children with nephrotic syndrome in 1980 (45) and 
continues to be used as a steroid sparing agent in many countries. 
Cyclosporine A (CsA), a calcineurin inhibitor, was first isolated 
from the fungus Tolypocladium inflatum found in a soil sample 
obtained in 1969 from Norway, by Hans Peter Frey (46). It was 
initially used in humans for renal transplantation in 1978 and 
has since changed the face of transplantation (47). The first use 
for CsA was reported in 1986 among adults with difficult to treat 
nephrotic syndrome (48). By the late 1980s, there were reports 
of its successful use in children with steroid-resistant or steroid-
dependent nephrotic syndrome that had not responded well to 
alkylating agents with the target levels of CsA between 50 and 
200 ng/ml (49, 50).
Tacrolimus, another calcineurin inhibitor, was first extracted 
from Streptomyces tsukubaenis in 1987 by a Japanese group (51) 
and was initially used as a drug in human organ transplantation. 
Its use for nephrotic syndrome was first started in adults in the 
early 1990s (52–54) and then reported to be used children by the 
early 2000s (55–57). It was shown to be similar to CsA with regard 
to efficacy and renal toxicity but without the cosmetic side effects 
of hirsutism and gingival hypertrophy (58).
Mycophenolate mofetil (cellcept®) and, more recently, 
mycophenolate sodium (myfortic®) are prodrug forms of 
mycophenolic acid, another purine synthesis inhibitor, identified 
from Penicillium species. It was first reported to be used in pedi-
atric nephrotic syndrome in 2000 (59) after being successfully 
applied in other glomerular diseases (60) and renal transplanta-
tion. It has been shown to be useful in steroid-dependent and 
frequently relapsing steroid-sensitive nephrotic syndrome, as a 
first-line agent, although there is evidence to indicate that it is 
probably less effective that calcineurin inhibitors (43, 61–63).
Rituximab, a monoclonal antibody against a B-lymphocyte 
antigen CD20, came into the armamentarium after case reports 
describing the incidental finding of a beneficial effect of rituxi-
mab on childhood nephrotic syndrome (64). Benz et  al. first 
used rituximab to treat ITP, resistant to steroids and immuno-
globulin therapy, in a 16-year-old boy who also suffered from 
steroid-dependent nephrotic syndrome. As well as effectively 
resolving the ITP, rituximab also improved the nephrotic syn-
drome, inducing a relapse-free period for over 12  months on 
low-dose CsA (65). In the other two cases, rituximab was used 
to treat post-transplant lymphoproliferative disease (PTLD) 
in boys who also had recurrence of FSGS in their transplants 
(66, 67), with beneficial effects on proteinuria. Its efficacy was 
recently demonstrated as a steroid-sparing agent in childhood 
onset frequently relapsing and steroid-dependent nephrotic 
syndrome by a multicenter, double-blind, randomized, and 
placebo-controlled trial (68) conducted by Iijima et al. Patients 
in the rituximab-treated group were relapse-free for prolonged 
period of time despite being weaned off other immunosup-
pressants such as mycophenolate or cyclosporine. There have 
been few case reports of its efficacy in refractory primary FSGS; 
however, controlled clinical trails are needed to define its exact 
role (69, 70). It has been proven to be effective in combination 
with plasmapheresis for post-transplant recurrence of FSGS (70, 
71). Part of this effect may be mediated by its direct action on 
the podocyte (72).
FUTURe TReATMeNTS  
AND CONCLUSiON
Interestingly, ACTH is currently remerging as a potential 
treatment for nephrotic syndrome. In Europe, it is available as 
a synthetic depot formulation (Synacthen®) and in the US as 
a highly purified formulation (Acthar® gel) from porcine or 
bovine sources (73). There are reports on its efficacy in multiple 
causes of nephrotic syndrome, including idiopathic membranous 
nephropathy, FSGS, minimal-change disease, and mesangial glo-
merulonephritis, with a response rate varying from 29 to 100% 
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(73–79). Recently, it has been shown to be particularly beneficial 
in idiopathic membranous nephropathy. Although the exact 
mechanism of action for ACTH is not known, it is thought to 
act directly on the podocytes via melanocortin receptors on the 
podocytes. There is need for a multicenter randomized control 
trial to assess its use in idiopathic nephrotic syndrome.
With discovery of various gene defects associated with 
nephrotic syndrome, there is an expanding knowledge of various 
podocyte signaling pathways that play a role in the pathogenesis 
of nephrotic syndrome (80). A better understanding of these 
pathways is needed to develop future targeted therapy. The high 
risk variant genotype of APOL1 gene (codes of apolipoprotein 1, 
known for its trypanolytic properties), was found to confer 
increased risk to kidney disease by gene-wide association studies 
(GWAS) (81–83). However, its association and role in nephrotic 
syndrome and podocyte biology are yet to be defined (80). New 
drugs on the horizon, such as losmapimod (p38 MAPK inhibi-
tor), sparsentan (endothelin receptor type 1A antagonist), and 
biologics, such as adalimumab (anti-TNF-α) and abatacept 
(anti-CD80), hold promise in the treatment of steroid-resistant 
nephrotic syndrome and prevention of renal progression (79).
In summary, the seminal contributions of the ISKDC identi-
fied the importance of global collaborations in order to conduct 
meaningful multicenter trials aimed at effectively treating 
children with nephrotic syndrome, preventing renal progression 
and facilitating the opportunity for each child to reach their full 
potential and quality of life. The availability of advanced genetic 
and molecular applications to personalized medicine offer unique 
opportunities along this promising journey.
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